• Emerging Treatments for Cold Agglutinin Disease

  • Aug 30 2021
  • Duración: 12 m
  • Podcast

Emerging Treatments for Cold Agglutinin Disease Por arte de portada

Emerging Treatments for Cold Agglutinin Disease

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

    • Unmet medical need due to the high frequency of persistent anemia/hemolysis; immunochemotherapy is unsuccessful in at least 25% of cases because of treatment failure or toxicity; and small B-cell clone shows low proliferation activity and is difficult to target efficiently
    • Need for rapid acting therapy, especially in specific clinical settings, such as acute and severe exacerbations due to infections, major surgery, trauma, cardiac surgery
    • As of June 2021, there were six emerging treatments in trials, including Eculizumab, Bortezomib, Sutimlimab (BIVV009) in the CARDINAL and CADENZA trials, Pegcetacoplan (APL-2) and BIVV020 (both multiple and single IV doses)
    • The CADENCE Registry, a global patient registry launched in 2019, is an important tool in treating CAD and will provide perspective longitudinal data to advance understanding of patient demographics, clinical presentation and characteristics, co-morbidities and disease burden, patterns and use of CA
    Más Menos
activate_primeday_promo_in_buybox_DT
Más Menos

Lo que los oyentes dicen sobre Emerging Treatments for Cold Agglutinin Disease

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles